Preliminary Study on the Diagnostic Value of Ultrasonic Shear Wave Dispersion for High-risk Esophageal Gastric Varices in Cirrhosis

Jiayin Wang; Hongyu Zhou; Tinghong Li; Chuan Liu; Lei Zhao; Baiguo Xu; Weili Yin; Fang Wang; Jing Liang; Xiang Jing; Huiling Xiang

doi:10.1101/2022.11.11.22282074

Abstract

Objective To explore the clinical value of two-dimensional ultrasonic shear wave elastography (SWE) and shear wave dispersion (SWD) in the diagnosis of high-risk esophageal gastric varices with cirrhosis.

Methods A total of 123 people were included, which were divided into the high-risk esophageal gastric varices (high-risk EGV) group (n =60) and low-risk esophageal gastric varices (low-risk EGV) group (n =63). Both shear wave elastography (SWE) and SWD were adopted to examine each patient’s liver synchronously with the Doppler ultrasonic instrument.

Results In total patients, the results of SWD and SWE of the high-risk EGV group were significantly higher than low-risk EGV group respectively. According to SWD examination, the area under the curve (AUC) of high-risk EGV was 0.709(95%CI:0.616-0.802), the optimal cutoff value was 14.35 m/s/kHz, the sensitivity and specificity was 81.7% and 57.1%, the AUC of high-risk EGV in patients with compensated cirrhosis was 0.786(95%CI:0.656-0.916), the optimal cutoff value was 14.35 m/s/kHz, the sensitivity and specificity was 86.4% and 61.1%, while the AUC of high-risk EGV in patients with decompensated cirrhosis was 0.637(95%CI: 0.494-0.780). According to SWE, the AUC of high-risk EGV in all patients, patients with compensated cirrhosis, and patients with decompensated cirrhosis was 0.606(95%CI: 0.506-0.706), 0.596(95%CI: 0.449-0.743), and 0.579(95%CI: 0.434-0.725), respectively, indicating limited diagnostic value.

Conclusion SWD predicted the existence of high-risk EGV in patients with compensated cirrhosis non-invasively and provided a supplementary method to determine whether high-risk EGV exists or not in patients, while SWE had limited diagnostic value.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Sponsored by Tianjin Health Project. (No. TJWJ2022XK029）

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Ethics Committee of Tianjin Third Central Hospital (Document No. IRB2019-022-03)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes